- $631.35m
- $519.81m
- $311.71m
Brief: CorMedix Inc Reports Second Quarter And Six Month 2023 Financial Results
CorMedix Inc expected to post a loss of 24 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Micron, Greenbrier, Immunome
U.S. STOCKS ON THE MOVE-Sigilon, Netflix, RenovoRx
U.S. STOCKS ON THE MOVE-Virgin Galactic, Occidental Petroleum, Joby Aviation
CorMedix tumbles on pricing $40 mln stock offering
Brief: Cormedix Inc. Announces Pricing Of $40 Million Public Offering Of Common Stock And Pre-Funded Warrants
CorMedix tumbles on stock offering
Brief: CorMedix Inc Announces FDA Acceptance Of Resubmission Of New Drug Application For DefenCath
Brief: CorMedix Announces Strategic Initiative With Boston Medical Center
Brief: Cormedix Inc Announces Resubmission Of New Drug Application For Defencath
Brief: CorMedix Reports First Quarter 2023 Financial Results
CorMedix Inc reports results for the quarter ended in March - Earnings Summary
CorMedix Inc expected to post a loss of 20 cents a share - Earnings Preview
CorMedix Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: CorMedix Inc Announces Notice Of Allowance For U.S. Patent Application Covering Lead Product Defencath
Brief: Cormedix Announces Regulatory, Manufacturing And Reimbursement Updates
Brief: Cormedix Inc Announces Appointment Of Robert A. Stewart To Its Board Of Directors
CorMedix Inc reports results for the quarter ended in December - Earnings Summary